Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Bimosiamose on ozone-induced sputum neutrophilia in healthy subjects
2009-013163-18Phase 2Completed
- Sponsor
- Revotar Biopharmaceuticals
- Start
- Jun 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimosiamose in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Revotar Biopharmaceuticals. Primary endpoint: Ratio of neutrophil counts under Bimosiamose and placebo. Started Jun 2009; status: completed.
02
Drugs
bimosiamose
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-013163-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013163-18.